Lilly’s Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing…
Eli Lilly and Company announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound (tirzepatide) provided a 47% greater relative weight loss…
Read More...
Read More...
